Product image of Halaven (Eribulin) supplied by GNH India

Halaven

Active Ingredient:
Eribulin
Origin:
EU

Halaven (Eribulin)

Halaven is a prescription injectable solution that contains the active ingredient eribulin. It is supplied in a standard strength (specific milligram amount varies by market) and is administered intravenously. Classified as a microtubule inhibitor and antineoplastic agent, Halaven is used in the European Union for the treatment of certain advanced cancers. Its mechanism involves inhibition of microtubule growth, leading to cell‑cycle arrest and apoptosis in patients.

Manufacturer / TM Owner

Eisai Gmbh

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Halaven (eribulin) is indicated for intravenous treatment of adult patients with specific malignant tumors that have progressed after prior chemotherapy. The drug is approved in the European Union for use in two main cancer types, reflecting its activity against rapidly dividing cells.

  • Metastatic breast cancer that has received at least two prior chemotherapeutic regimens
  • Advanced (unresectable or metastatic) liposarcoma after prior anthracycline‑containing therapy
  • Patients with disease progression despite standard therapies
  • Use as part of a multidisciplinary oncology treatment plan

Side Effects

Side effects of Halaven vary in frequency and severity. They are reported by patients receiving the intravenous formulation.

Common

  • Fatigue
  • Neutropenia
  • Anemia
  • Nausea
  • Alopecia
  • Peripheral neuropathy
  • Constipation

Serious

  • Febrile neutropenia
  • Severe infection
  • Pulmonary toxicity
  • Cardiac dysfunction
  • Tumor lysis syndrome
  • Severe allergic reactions

Precautions & Warnings

Before initiating Halaven, clinicians should evaluate patient history and monitor for potential risks associated with antineoplastic therapy.

  • Assess baseline blood counts and organ function
  • Monitor for signs of infection or febrile neutropenia
  • Evaluate cardiac status in patients with pre‑existing heart disease
  • Use caution in patients with hepatic impairment
  • Counsel patients on the risk of peripheral neuropathy and provide supportive care measures
  • Discuss contraception and pregnancy considerations, as safety data are limited

Avoid Interactions

Halaven may interact with other medications that affect bone marrow function or hepatic metabolism. Awareness of these interactions helps reduce adverse outcomes.

Avoid

  • Concurrent use of other myelosuppressive chemotherapy agents
  • Strong CYP3A4 inducers that could reduce eribulin exposure
  • Live vaccines during treatment due to immunosuppression

Use with caution

  • Antifungal agents that are CYP3A4 substrates
  • Medications that prolong QT interval
  • Drugs that affect platelet function
  • Herbal supplements that influence liver enzymes

Frequently Asked Questions

Halaven is approved for metastatic breast cancer that has progressed after at least two prior chemotherapy regimens and for advanced (unresectable or metastatic) liposarcoma following prior anthracycline‑containing therapy.

Halaven is supplied as an injectable solution and is given intravenously by a qualified healthcare professional according to the prescribed schedule.

Eribulin inhibits the growth phase of microtubules, causing G2‑M cell‑cycle arrest and ultimately leading to apoptosis of cancer cells.

Common side effects include fatigue, neutropenia, anemia, nausea, alopecia, peripheral neuropathy, and constipation.

Serious reactions to watch for are febrile neutropenia, severe infections, pulmonary toxicity, cardiac dysfunction, tumor lysis syndrome, and severe allergic reactions.

Baseline complete blood counts, liver function tests, and cardiac assessments are typically performed to ensure patient suitability for treatment.

Concurrent use of other myelosuppressive chemotherapy agents is generally avoided to reduce the risk of severe bone‑marrow suppression.

Avoid strong CYP3A4 inducers and live vaccines during treatment. Use caution with CYP3A4 substrates, QT‑prolonging drugs, and agents affecting platelet function.

Dose adjustments may be required for patients with hepatic impairment; clinicians should evaluate liver function tests and follow prescribing guidelines.

Patients should be advised about the risk of infection, signs of neutropenia, potential neuropathy, the importance of reporting new symptoms, and contraception use during treatment.

The specific dosing interval is determined by the prescribing oncologist and may vary based on the treatment protocol and patient response.

Regular monitoring of blood counts, liver function, cardiac status, and assessment for signs of infection or neuropathy is recommended throughout treatment.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Eribulin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT